If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Hong Kong developed into a filmmaking hub during the late 1940s as a wave of Shanghai filmmakers migrated to the territory, and these movie veterans helped build the colony's entertainment industry over the next decade. By the 1960s, the city was well known to overseas audiences through films such as The World of Suzie Wong. When Bruce Lee's The Way of the Dragon was released in 1972 and Enter the Dragon in 1973, local productions became popular outside Hong Kong. During the 1980s and 1900s, films such as A Better Tomorrow, As Tears Go By, God of Gamblers, Police Story and Zu Warriors from the Magic Mountain expanded global interest beyond martial arts films; locally made gangster films, romantic dramas, and supernatural fantasies became popular.
== Adverse effects == Although not as widely published as the beneficial, therapeutic effects of cannabis tea, adverse effects of consumption have been found to exist, in addition to the known adverse effects of cannabis use in general. Based upon the findings of select studies, it appears as though such effects occur mainly as a result of unconventional methods or dosage used when interacting with the decoction.
== Symptoms == Some signs and symptoms that are frequently exhibited in patients with SJS include epiphyseal abnormalities, metaphyseal abnormalities, arthrogryposis multiplex congenita, bowing of long bones, a protruding lower lip, full cheeks, a disturbed gait, genu valgum, hip dysplasia, hypertonia, intellectual disability, joint stiffness, low-set posteriorly-rotated ears, metatarsus valgus, micromelia, myotonia, narrow mouth, flat foot, pursed lips, short stature, skeletal dysplasia, trismus, and visual impairment.
=== Origins === The Centre Party belongs to the political spectrum of "Political Catholicism" that, emerging in the early 19th century after the turmoil of the Napoleonic wars, had changed the political face of Germany. Many Catholics found themselves in Protestant dominated states. The first major conflict between the Catholic Church and a Protestant state was the "Colonian Church conflict", when the Prussian government interfered in the question of mixed marriages and the religious affiliation of children resulting from these. This led to serious aggressions against the Catholic population of the Rhineland and Westphalia and culminated in the arrest of the Archbishop of Cologne. At that time, one of the founding fathers of Political Catholicism was journalist Joseph Görres, who called upon Catholics to "stand united" for their common goals, "religious liberty and political and civil equality of the denominations". The conflict relaxed after 1840, with Frederick William IV's accession to the throne. The German revolutions of 1848–1849 brought new opportunities for German Catholics. In October, the bishops had their first meeting in 40 years in Würzburg and the local "Catholic Federations" assembled in Mainz to found the "Catholic Federation of Germany". In the National Assembly, which was convened to draw up a German constitution, a "Catholic club" was formed. This was not yet a comprehensive party, but a loose union aimed at protecting the Church's liberties in a future Germany, supported by many petitions from the "[Pope] Pius federations for religious liberty".
Sources: en.wikipedia.org
== Abstracting and indexing == The journal is abstracted and indexed by Chemical Abstracts Service, MEDLINE/PubMed, Scopus, and the Science Citation Index Expanded. According to the Journal Citation Reports, the journal has a 2025 impact factor of 2.6.
=== Production === Aqueous humour is secreted into the posterior chamber by the ciliary body, specifically the non-pigmented epithelium of the ciliary body (pars plicata). 5 alpha-dihydrocortisol, an enzyme inhibited by 5-alpha reductase inhibitors, may be involved in production of aqueous humour.
== Hosts and disease development == Penicillium expansum has a wide host range, causing similar symptoms on fruits which include apples, pears, cherries, and citrus. Initial infection most often occurs at sites of fruit injury, such as bruises or puncture wounds. Although infections may start in the field, infected spots often become evident post-harvest, and expand while fruit is in storage. Infected areas are clearly delineated and light brown, and soft decaying tissue can be easily "scooped" out of the surrounding healthy tissue. Spore masses later appear on the surfaces of infected fruit, initially appearing as white mycelium, then turning blue to blue-green in color as the asexual spores mature. Fruit affected by P. expansum typically has an earthy, musty odor. Lesions measure 1–1.25 inches in diameter eight to ten weeks after infection if kept under cold storage conditions. Age factors into P. expansum infection, in that overripe or mature fruits are most susceptible to infection, while those picked underripe are less likely to become infected. In apples, the colors of the lesions may vary with variety, from lighter-brown on green and yellow apple varieties, to dark-brown on the deeper-red and other darker-color varieties. Varieties particularly susceptible to P. expansum infection include McIntosh, Golden Supreme, and Golden Delicious. Both sweet and sour cherries are affected by P. expansum. Cherry varieties found to be particularly susceptible to P. expansum infection were mainly early varieties, including Navalinda and Burlat.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.